12,091 Shares in RxSight, Inc. (NASDAQ:RXST) Purchased by Intech Investment Management LLC

Intech Investment Management LLC purchased a new stake in RxSight, Inc. (NASDAQ:RXST) during the 3rd quarter, HoldingsChannel.com reports. The fund purchased 12,091 shares of the company’s stock, valued at approximately $598,000.

Several other hedge funds have also recently bought and sold shares of RXST. CWM LLC increased its position in RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after buying an additional 371 shares during the period. Nisa Investment Advisors LLC increased its stake in RxSight by 854.1% in the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock valued at $29,000 after acquiring an additional 521 shares during the last quarter. Quest Partners LLC acquired a new position in shares of RxSight during the 2nd quarter worth $41,000. Amalgamated Bank lifted its holdings in shares of RxSight by 21.3% in the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after acquiring an additional 207 shares during the last quarter. Finally, KBC Group NV grew its stake in shares of RxSight by 63.6% during the third quarter. KBC Group NV now owns 1,232 shares of the company’s stock worth $61,000 after buying an additional 479 shares during the last quarter. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on RXST shares. Stifel Nicolaus cut their price target on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Jefferies Financial Group assumed coverage on RxSight in a research note on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price target for the company. Oppenheimer cut their price objective on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and set a $66.00 target price on shares of RxSight in a research report on Friday, September 13th. Finally, Wells Fargo & Company lowered their price target on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $61.63.

RxSight Price Performance

RXST stock opened at $46.88 on Friday. The company’s 50-day moving average is $48.58 and its 200-day moving average is $52.31. The stock has a market capitalization of $1.89 billion, a PE ratio of -56.48 and a beta of 1.19. RxSight, Inc. has a 1 year low of $28.88 and a 1 year high of $66.54.

Insider Buying and Selling

In other news, insider Ilya Goldshleger sold 3,100 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $52.67, for a total value of $163,277.00. Following the completion of the transaction, the insider now directly owns 42,246 shares of the company’s stock, valued at $2,225,096.82. This represents a 6.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Shweta Maniar sold 3,782 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total value of $173,518.16. Following the sale, the director now directly owns 10,902 shares of the company’s stock, valued at $500,183.76. The trade was a 25.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 62,702 shares of company stock valued at $3,059,197. 9.36% of the stock is owned by company insiders.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.